Stanford Graduate School of Business (USA)
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems - Teaching Note
Chess, R; Luthre, JTeaching Note SGSB-E489TN-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €0.00
-
Ashoka: Innovators for the Public
Meehan, B; Levenson, Keohane, GCase SGSB-SM203-EStrategySince its founding in 1980, Ashoka: Innovators for the Public had supported the work of over 3,000 of the world’s most visionary social entrepreneurs; men and women who, in Ashoka founder Bill Drayton’s words, are tireless pioneers of “system-changing solutions that advance the world’s most urgent social problems.” Through these efforts, Ashoka was also widely credited with building the larger field of social entrepreneurship. And yet, just at t...Starting at €8.20
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems
Chess, R; Luthre, JCase SGSB-E489-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €8.20